Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
NCT03452072Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of timolol maleate gel + placebo in surgical wound (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Number of Participants With Re-epithelialization at 30 days. Started Aug 2018; status: completed.
02
Drugs
timolol maleate gel + placebo
03
Conditions
surgical wound
Beyond the preview
Go deeper on NCT03452072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452072.